Integrated approach of drug development

Preclinical drug development is a complex, regulatory and strategy-driven process. The most important element of the preclinical process is to select the best new molecular entities to enter into the clinical trials and to limit failure in full development.  With its countless years of professional experience in drug development Eurofins Pharma Services is well positioned to offer a holistic approach of the compound development in order to maximize the chances of success in the clinical phases. Our network of expertise and full service is not only a matter of convenience but also an issue of confidence and security to succeed with your project. Our clients select Eurofins for this distinctive match of expertise, flexibility and full service. This beneficial setting explains why we work for 8 out of the 10 biggest Pharma companies.   

Complete preclinical Service

Early development Phase I and IIa studies

We have with Eurofins ׀ Optimed more than 80 beds in our clinical Phase I and IIa units based in Grenoble and Lyon (F). Patient safety, an efficient recruitment policy and the network of expertise within Eurofins are responsible for our outstanding reputation in the pharmaceutical, cosmetic and nutrition industry. The complete integration of Eurofins preclinical capabilities and clinical units into a full service of drug development is a real benefit for our clients. Eurofins ׀ Optimed provides an inclusive service during Phase I and IIa studies including e.g. bioanalysis, data management and preparation of the dossiers. For the next steps of the clinical development, Eurofins Pharma Services provide an outstanding support in the complex process for logistics, biomarker development, central lab and data management.